fda approves first oral glp-1 obesity drug august 21 2025 New Pill Foundayo (Orforglipron) Gets Approval for The FDA approved a new

Linked below are a few resources to learn more about eating disorders, eating disorder prevention, and fatphobia

Unlike regulators in India and China, the FDA does not require most generic drug makers to conduct human clinical trials if they can demonstrate that the generic version is chemically equivalent to the original drug

The hope is that tirzepatide could tamp down this inflammation to improve patients symptoms

Weight management GLP-1s have been seen as gamechangers from a clinical standpoint, helping people shed significant weight when paired with lifestyle modification

Microdosing could be part of step-down support as a way to help sustain appetite regulation and provide a soft landing after complete discontinuation. Im not overweight, but I want the other benefits

We expect to see more pack trade-offs in potato chips, soft drinks and cold cereal but we also see outsized pack trade-offs in coffee and granola, which implies two emerging trends in the GLP-1 population: a general decrease in snacking, even for snacks usually considered healthy, and overall collateral damage that is spreading to categories that should not be greatly affected by GLP-1 status. In addition to their impact on the retail food and beverage market, oral GLP-1 medications are expected to account for 20% of total GLP-1 drug sales by 2031, with a pill market that is estimated to grow from $3.2 billion in 2025 to $34.3 billion in 2031, according to GlobalData.